Trade Daré Bioscience, Inc. - DARE CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.0056 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 0.3162 |
Open* | 0.3182 |
1-Year Change* | -64.14% |
Day's Range* | 0.2857 - 0.3184 |
52 wk Range | 0.28-1.40 |
Average Volume (10 days) | 356.84K |
Average Volume (3 months) | 5.16M |
Market Cap | 33.39M |
P/E Ratio | -100.00K |
Shares Outstanding | 98.56M |
Revenue | 1.00M |
EPS | -0.48 |
Dividend (Yield %) | N/A |
Beta | 1.13 |
Next Earnings Date | Mar 28, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 7, 2023 | 0.3162 | -0.0450 | -12.46% | 0.3612 | 0.3612 | 0.3068 |
Dec 6, 2023 | 0.3402 | -0.0151 | -4.25% | 0.3553 | 0.3553 | 0.3382 |
Dec 5, 2023 | 0.3480 | -0.0102 | -2.85% | 0.3582 | 0.3592 | 0.3447 |
Dec 4, 2023 | 0.3582 | 0.0040 | 1.13% | 0.3542 | 0.3881 | 0.3482 |
Dec 1, 2023 | 0.3481 | 0.0025 | 0.72% | 0.3456 | 0.3559 | 0.3387 |
Nov 30, 2023 | 0.3467 | -0.0016 | -0.46% | 0.3483 | 0.3533 | 0.3412 |
Nov 29, 2023 | 0.3483 | 0.0063 | 1.84% | 0.3420 | 0.3555 | 0.3332 |
Nov 28, 2023 | 0.3402 | 0.0020 | 0.59% | 0.3382 | 0.3484 | 0.3328 |
Nov 27, 2023 | 0.3441 | -0.0042 | -1.21% | 0.3483 | 0.3620 | 0.3312 |
Nov 24, 2023 | 0.3435 | 0.0203 | 6.28% | 0.3232 | 0.3537 | 0.3232 |
Nov 22, 2023 | 0.3301 | 0.0018 | 0.55% | 0.3283 | 0.3360 | 0.3277 |
Nov 21, 2023 | 0.3370 | -0.0012 | -0.35% | 0.3382 | 0.3423 | 0.3232 |
Nov 20, 2023 | 0.3383 | 0.0071 | 2.14% | 0.3312 | 0.3592 | 0.3312 |
Nov 17, 2023 | 0.3340 | 0.0008 | 0.24% | 0.3332 | 0.3532 | 0.3150 |
Nov 16, 2023 | 0.3272 | -0.0110 | -3.25% | 0.3382 | 0.3439 | 0.3232 |
Nov 15, 2023 | 0.3382 | -0.0100 | -2.87% | 0.3482 | 0.3522 | 0.3337 |
Nov 14, 2023 | 0.3406 | 0.0097 | 2.93% | 0.3309 | 0.3437 | 0.3249 |
Nov 13, 2023 | 0.3333 | 0.0251 | 8.14% | 0.3082 | 0.3623 | 0.2992 |
Nov 10, 2023 | 0.3232 | -0.0150 | -4.44% | 0.3382 | 0.3458 | 0.3232 |
Nov 9, 2023 | 0.3182 | -0.0411 | -11.44% | 0.3593 | 0.3693 | 0.3182 |
Daré Bioscience, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, March 28, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q4 2023 Dare Bioscience Inc Earnings Release Q4 2023 Dare Bioscience Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 10 | 0 | 0 | 0 | 0 |
Total Operating Expense | 41.3855 | 38.6986 | 27.4023 | 14.3449 | 16.8823 |
Selling/General/Admin. Expenses, Total | 11.3433 | 8.45095 | 6.63284 | 5.79877 | 5.28084 |
Research & Development | 30.0422 | 30.6176 | 20.7694 | 8.54611 | 6.41396 |
Unusual Expense (Income) | 0 | -0.36989 | 0 | 5.18752 | |
Operating Income | -31.3855 | -38.6986 | -27.4023 | -14.3449 | -16.8823 |
Interest Income (Expense), Net Non-Operating | |||||
Net Income Before Taxes | -30.9477 | -38.6961 | -27.4007 | -14.2638 | -16.7388 |
Net Income After Taxes | -30.9477 | -38.6961 | -27.4007 | -14.2638 | -16.7388 |
Net Income Before Extra. Items | -30.9477 | -38.6961 | -27.4007 | -14.2638 | -16.7388 |
Net Income | -30.9477 | -38.6961 | -27.4007 | -14.2638 | -16.7388 |
Income Available to Common Excl. Extra. Items | -30.9477 | -38.6961 | -27.4076 | -15.0534 | -16.7388 |
Income Available to Common Incl. Extra. Items | -30.9477 | -38.6961 | -27.4076 | -15.0534 | -16.7388 |
Diluted Net Income | -30.9477 | -38.6961 | -27.4076 | -15.0534 | -16.7388 |
Diluted Weighted Average Shares | 84.5718 | 61.1542 | 30.0915 | 15.579 | 10.7324 |
Diluted EPS Excluding Extraordinary Items | -0.36593 | -0.63276 | -0.91081 | -0.96627 | -1.55965 |
Diluted Normalized EPS | -0.36593 | -0.63881 | -0.91081 | -0.96627 | -1.0763 |
Total Extraordinary Items | |||||
Other, Net | 0.43775 | 0.00252 | 0.00151 | 0.08105 | 0.1435 |
Total Adjustments to Net Income | 0 | -0.00686 | -0.78959 | ||
Revenue | 10 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 10 |
Total Operating Expense | 8.98936 | 8.38265 | 16.2306 | 7.13879 | 9.61568 |
Selling/General/Admin. Expenses, Total | 2.94567 | 3.36243 | 3.25385 | 2.67654 | 2.81789 |
Research & Development | 6.04368 | 5.02022 | 12.9767 | 4.46225 | 6.79778 |
Unusual Expense (Income) | 0 | 0 | 0 | ||
Operating Income | -8.98936 | -8.38265 | -16.2306 | -7.13879 | 0.38432 |
Other, Net | 0.22712 | 0.34015 | 0.28734 | 0.11895 | 0.02968 |
Net Income Before Taxes | -8.76223 | -8.0425 | -15.9432 | -7.01984 | 0.414 |
Net Income After Taxes | -8.76223 | -8.0425 | -15.9432 | -7.01984 | 0.414 |
Net Income Before Extra. Items | -8.76223 | -8.0425 | -15.9432 | -7.01984 | 0.414 |
Net Income | -8.76223 | -8.0425 | -15.9432 | -7.01984 | 0.414 |
Income Available to Common Excl. Extra. Items | -8.76223 | -8.0425 | -15.9432 | -7.01984 | 0.414 |
Income Available to Common Incl. Extra. Items | -8.76223 | -8.0425 | -15.9432 | -7.01984 | 0.414 |
Diluted Net Income | -8.76223 | -8.0425 | -15.9432 | -7.01984 | 0.414 |
Diluted Weighted Average Shares | 86.4031 | 85.5175 | 81.6278 | 84.8225 | 85.3694 |
Diluted EPS Excluding Extraordinary Items | -0.10141 | -0.09405 | -0.19532 | -0.08276 | 0.00485 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.10141 | -0.09405 | -0.19532 | -0.08276 | 0.00485 |
Total Adjustments to Net Income | |||||
Revenue | 0 | 0 | 0 | 10 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 43.0387 | 55.296 | 6.98391 | 6.44393 | 7.24002 |
Cash and Short Term Investments | 34.6696 | 51.6741 | 4.66947 | 4.78011 | 6.80589 |
Cash & Equivalents | 34.6696 | 51.6741 | 4.66947 | 4.78011 | 6.80589 |
Total Assets | 43.8264 | 55.8072 | 7.55071 | 7.44279 | 7.82739 |
Total Current Liabilities | 31.6239 | 16.0529 | 7.6606 | 5.61241 | 1.09106 |
Payable/Accrued | |||||
Accrued Expenses | 11.2924 | 3.40679 | 3.70743 | 2.50955 | 0.63135 |
Notes Payable/Short Term Debt | 0 | 0 | 0.36729 | 0 | 0 |
Total Liabilities | 32.7143 | 17.0529 | 8.70245 | 7.00196 | 1.10077 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 1.09035 | 1 | 1.04184 | 1.38956 | 0.00971 |
Total Equity | 11.1121 | 38.7543 | -1.15173 | 0.44083 | 6.72662 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.00848 | 0.00839 | 0.00416 | 0.00197 | 0.00114 |
Additional Paid-In Capital | 152.53 | 149.028 | 70.3663 | 44.5647 | 35.792 |
Retained Earnings (Accumulated Deficit) | -141.075 | -110.127 | -71.4308 | -44.0232 | -28.9698 |
Total Liabilities & Shareholders’ Equity | 43.8264 | 55.8072 | 7.55071 | 7.44279 | 7.82739 |
Total Common Shares Outstanding | 84.8255 | 83.9441 | 41.5962 | 19.6834 | 11.4222 |
Total Receivables, Net | 1.70316 | 1.14532 | 0.46017 | 0.55521 | 0.03104 |
Prepaid Expenses | 6.66599 | 2.47661 | 1.85428 | 1.10862 | 0.4031 |
Other Current Assets, Total | 0 | ||||
Goodwill, Net | 0 | ||||
Other Long Term Assets, Total | 0.2648 | 0.26845 | 0.28932 | 0.44733 | 0.57797 |
Other Equity, Total | -0.35131 | -0.15497 | -0.09139 | -0.10263 | -0.09673 |
Property/Plant/Equipment, Total - Net | 0.52283 | 0.24271 | 0.27748 | 0.55153 | 0.0094 |
Accounts Payable | 2.02795 | 2.10308 | 1.02133 | 1.08318 | 0.45971 |
Other Current Liabilities, Total | 18.3036 | 10.543 | 2.56455 | 2.01967 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 22.4355 | 22.2433 | 29.5119 | 43.0387 | 49.5671 |
Cash and Short Term Investments | 13.8944 | 13.3291 | 19.8294 | 34.6696 | 40.3895 |
Cash & Equivalents | 13.8944 | 13.3291 | 19.8294 | 34.6696 | 40.3895 |
Total Receivables, Net | 1.12976 | 0.57247 | 2.39871 | 1.70316 | 2.29204 |
Prepaid Expenses | 6.57993 | 8.06962 | 7.08245 | 6.66599 | 6.8855 |
Total Assets | 25.054 | 23.2099 | 30.3667 | 43.8264 | 50.3764 |
Property/Plant/Equipment, Total - Net | 0.24062 | 0.32179 | 0.4234 | 0.52283 | 0.61883 |
Other Long Term Assets, Total | 2.37791 | 0.64488 | 0.43133 | 0.2648 | 0.19051 |
Total Current Liabilities | 26.3428 | 24.7008 | 24.3379 | 31.6239 | 22.8381 |
Accounts Payable | 4.9874 | 6.54112 | 2.69561 | 2.02795 | 3.47719 |
Accrued Expenses | 5.48783 | 4.46562 | 5.81597 | 11.2924 | 4.52447 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 15.8675 | 13.6941 | 15.8264 | 18.3036 | 14.8364 |
Total Liabilities | 27.3428 | 25.9294 | 25.3951 | 32.7143 | 24.0327 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 1 | 1.22853 | 1.05713 | 1.09035 | 1.19459 |
Total Equity | -2.28874 | -2.7194 | 4.9716 | 11.1121 | 26.3438 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.00983 | 0.00866 | 0.00862 | 0.00848 | 0.00848 |
Additional Paid-In Capital | 164.299 | 155.556 | 154.453 | 152.53 | 151.997 |
Retained Earnings (Accumulated Deficit) | -166.178 | -157.879 | -149.117 | -141.075 | -125.131 |
Other Equity, Total | -0.4195 | -0.40447 | -0.37332 | -0.35131 | -0.53074 |
Total Liabilities & Shareholders’ Equity | 25.054 | 23.2099 | 30.3667 | 43.8264 | 50.3764 |
Total Common Shares Outstanding | 98.2923 | 86.6336 | 86.179 | 84.8255 | 84.8255 |
Accounts Receivable - Trade, Net | |||||
Other Current Assets, Total | 0.83138 | 0.2721 | 0.20139 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -30.9477 | -38.6961 | -27.4007 | -14.2638 | -16.7388 |
Cash From Operating Activities | -18.0884 | -28.764 | -25.2349 | -13.3155 | -10.2684 |
Non-Cash Items | 2.13545 | 1.17796 | 0.57986 | 0.26014 | 5.83387 |
Cash Taxes Paid | 0 | ||||
Changes in Working Capital | 10.6997 | 8.7277 | 1.54273 | 0.67707 | 0.63408 |
Cash From Investing Activities | -0.06307 | -0.01452 | -0.01763 | 6.14389 | -0.51884 |
Other Investing Cash Flow Items, Total | 0 | 6.14389 | -0.507 | ||
Cash From Financing Activities | 1.34335 | 75.8468 | 25.1307 | 5.1517 | 10.1119 |
Issuance (Retirement) of Debt, Net | 0 | 0.36729 | 0 | ||
Foreign Exchange Effects | -0.19634 | -0.06359 | 0.01124 | -0.0059 | -0.07865 |
Net Change in Cash | -17.0045 | 47.0046 | -0.11064 | -2.02578 | -0.75396 |
Cash Interest Paid | 0 | ||||
Cash From Operating Activities | 0.0242 | 0.02641 | 0.04323 | 0.01114 | 0.00244 |
Capital Expenditures | -0.06307 | -0.01452 | -0.01763 | 0 | -0.01184 |
Issuance (Retirement) of Stock, Net | 1.34335 | 75.8468 | 24.7634 | 5.1517 | 10.1119 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -8.0425 | -30.9477 | -15.0045 | -7.98467 | -8.39867 |
Cash From Operating Activities | -16.1176 | -18.0884 | -12.1918 | -20.792 | -12.3435 |
Cash From Operating Activities | 0.00951 | 0.0242 | 0.01358 | 0.01055 | 0.00523 |
Non-Cash Items | 0.61872 | 2.13545 | 1.60922 | 1.07987 | 0.52265 |
Changes in Working Capital | -8.70329 | 10.6997 | 1.18996 | -13.8977 | -4.47268 |
Cash From Financing Activities | 1.29938 | 1.34335 | 1.34336 | 1.3389 | 0 |
Issuance (Retirement) of Stock, Net | 1.29938 | 1.34335 | 1.34336 | 1.3389 | 0 |
Foreign Exchange Effects | -0.02201 | -0.19634 | -0.37577 | -0.14502 | -0.00915 |
Net Change in Cash | -14.8402 | -17.0045 | -11.2845 | -19.6035 | -12.3572 |
Cash From Investing Activities | 0 | -0.06307 | -0.06037 | -0.00537 | -0.00455 |
Capital Expenditures | 0 | -0.06307 | -0.06037 | -0.00537 | -0.00455 |
Issuance (Retirement) of Debt, Net |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.5045 | 3444675 | -15545 | 2023-06-30 | LOW |
Johnson (Sabrina Martucci) | Individual Investor | 0.9788 | 962062 | 0 | 2023-04-07 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8315 | 817336 | 0 | 2023-06-30 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.7313 | 718821 | 149762 | 2023-06-30 | HIGH |
Walters-Hoffert (Lisa) | Individual Investor | 0.4512 | 443512 | 0 | 2023-04-07 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.4054 | 398457 | -210486 | 2023-06-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.252 | 247710 | 0 | 2023-06-30 | LOW |
Steele Robin Joan | Individual Investor | 0.2504 | 246171 | 0 | 2023-04-07 | LOW |
Susquehanna International Group, LLP | Investment Advisor | 0.1669 | 164021 | 164021 | 2023-06-30 | MED |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1641 | 161316 | -352 | 2023-06-30 | LOW |
T. Rowe Price International Ltd | Investment Advisor/Hedge Fund | 0.1281 | 125900 | 0 | 2023-06-30 | LOW |
Founders Financial Securities, LLC | Investment Advisor | 0.1262 | 124000 | 10000 | 2023-09-30 | MED |
InterWest Partners | Venture Capital | 0.0631 | 62065 | 0 | 2023-09-30 | LOW |
Citadel Advisors LLC | Hedge Fund | 0.0508 | 49901 | -194740 | 2023-06-30 | LOW |
Commonwealth Financial Network | Investment Advisor | 0.0502 | 49329 | -250 | 2023-09-30 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.0311 | 30532 | 0 | 2023-06-30 | LOW |
BNY Mellon Asset Management | Investment Advisor | 0.0233 | 22947 | 0 | 2023-09-30 | LOW |
Raymond James Financial Services Advisors, Inc. | Investment Advisor | 0.0203 | 20000 | -10 | 2023-09-30 | LOW |
Advisory Services Network, LLC | Investment Advisor | 0.0153 | 15000 | 0 | 2023-06-30 | LOW |
Lord, Abbett & Co. LLC | Investment Advisor | 0.0151 | 14808 | 0 | 2023-07-31 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Daré Bioscience, Inc. Company profile
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women''s health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company''s Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.Industry: | Biotechnology & Medical Research (NEC) |
3655 Nobel Dr Ste 260
SAN DIEGO
CALIFORNIA 92122-1050
US
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com